On the other hand, CD34+ LSCs from CML patients were shown to express programmed death receptor ligand 1 (PD-L1) at diagnosis [171] whose expression was further upregulated in response to IFN-γ which could represent an interesting opportunity for T-cell immunotherapy of CML [172]. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.